Logo image of STI

SOLIDION TECHNOLOGY INC (STI) Stock Fundamental Analysis

NASDAQ:STI - Nasdaq - US8342121022 - Common Stock - Currency: USD

0.46  +0.07 (+17.92%)

Premarket: 0.4177 -0.04 (-9.2%)

Fundamental Rating

0

Taking everything into account, STI scores 0 out of 10 in our fundamental rating. STI was compared to 93 industry peers in the Electrical Equipment industry. STI has a bad profitability rating. Also its financial health evaluation is rather negative. STI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

STI had negative earnings in the past year.
STI had a negative operating cash flow in the past year.
STI Yearly Net Income VS EBIT VS OCF VS FCFSTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

STI has a worse Return On Assets (-569.49%) than 95.65% of its industry peers.
Industry RankSector Rank
ROA -569.49%
ROE N/A
ROIC N/A
ROA(3y)-9.34%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
STI Yearly ROA, ROE, ROICSTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 100 -100 200 300 400

1.3 Margins

STI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STI Yearly Profit, Operating, Gross MarginsSTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for STI has been reduced compared to 1 year ago.
STI has a worse debt/assets ratio than last year.
STI Yearly Shares OutstandingSTI Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M
STI Yearly Total Debt VS Total AssetsSTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -33.72, we must say that STI is in the distress zone and has some risk of bankruptcy.
STI has a Altman-Z score of -33.72. This is amonst the worse of the industry: STI underperforms 92.39% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -33.72
ROIC/WACCN/A
WACCN/A
STI Yearly LT Debt VS Equity VS FCFSTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M 60M 80M 100M

2.3 Liquidity

STI has a Current Ratio of 0.08. This is a bad value and indicates that STI is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.08, STI is doing worse than 93.48% of the companies in the same industry.
STI has a Quick Ratio of 0.08. This is a bad value and indicates that STI is not financially healthy enough and could expect problems in meeting its short term obligations.
STI's Quick ratio of 0.08 is on the low side compared to the rest of the industry. STI is outperformed by 93.48% of its industry peers.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.08
STI Yearly Current Assets VS Current LiabilitesSTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

STI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -4697.71%.
EPS 1Y (TTM)-4697.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-567.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
STI Yearly Revenue VS EstimatesSTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023
STI Yearly EPS VS EstimatesSTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STI Price Earnings VS Forward Price EarningsSTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STI Per share dataSTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

STI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLIDION TECHNOLOGY INC

NASDAQ:STI (2/4/2025, 10:30:52 PM)

Premarket: 0.4177 -0.04 (-9.2%)

0.46

+0.07 (+17.92%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryElectrical Equipment
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners18.15%
Inst Owner Change0.19%
Ins OwnersN/A
Ins Owner Change0%
Market Cap56.70M
Analysts72.4
Price TargetN/A
Short Float %4.13%
Short Ratio0.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.22
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS-0.15
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -569.49%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-9.34%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.08
Altman-Z -33.72
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4697.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-567.3%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-426.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-267%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-267%
OCF growth 3YN/A
OCF growth 5YN/A